Literature DB >> 18819966

Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?

A Fenoll1, L Aguilar, J J Granizo, M J Giménez, L Aragoneses-Fenoll, C Mendez, D Tarragó.   

Abstract

OBJECTIVES: The aim of the study was to analyse the evolution of antibiotic non-susceptibility in Spanish invasive Streptococcus pneumoniae after licensure of respiratory-quinolones for adults and 7-valent pneumococcal conjugate vaccine (PCV-7) for immunization of children.
METHODS: All invasive pneumococci received in the Reference Laboratory (January 2000-August 2007; n = 12 957 isolates) were serotyped, and susceptibility to penicillin/erythromycin/levofloxacin was determined. Antibiotic consumption and PCV-7 doses/year were provided by IMS and the manufacturer, respectively.
RESULTS: In 2000-07, PCV-7 distribution (doses/1000 inhabitants </=59 months age/year) increased from 0.0 to 411.90, and antibiotic consumption (DDD/1000 inhabitants/day) was maintained for beta-lactams ( approximately 16), decreased for macrolides (from 4.4 to 2.7) and increased for respiratory fluoroquinolones (from 0.3 to 2.7). The increase in PCV-7 distribution correlated with a decrease in PCV-7 serotypes prevalence among invasive isolates in children (r = -0.976; P < 0.001) and adults (r = -0.905; P = 0.002). This decrease in PCV-7 serotypes correlated with a decrease in penicillin non-susceptibility in children (r = 0.929; P < 0.001) and adults (r = 0.905; P = 0.002) and with erythromycin non-susceptibility in children (r = 0.833; P = 0.010). Penicillin/erythromycin non-susceptibility in 2000 was significantly higher in paediatric versus adult isolates (penicillin: 51.4% versus 29.2%; erythromycin: 39.5% versus 20.4%), but similar in 2006-07 (20% to 24%). The increase in respiratory quinolones consumption correlated with the increase in levofloxacin non-susceptibility in adults (r = 0.926; P = 0.008) but not in children, with different non-susceptibility rates in 2007 (1.6% versus 0.0%; P = 0.013).
CONCLUSIONS: This ecological analysis suggests that PCV-7 vaccination in children had a herd effect in adults, but consumption of respiratory quinolones in adults had no effect on pneumococcal susceptibility to levofloxacin in children. Penicillin/erythromycin non-susceptibility decreased along the studied period among paediatric invasive S. pneumoniae isolates to a level similar to that seen in adults.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18819966     DOI: 10.1093/jac/dkn413

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Serotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in Spain from 1997 to 2008.

Authors:  A Fenoll; L Aguilar; M D Vicioso; M J Gimenez; O Robledo; J J Granizo; C Mendez
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Susceptibility of recently collected Spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccine.

Authors:  Asunción Fenoll; Lorenzo Aguilar; María-José Giménez; María-Dolores Vicioso; Olga Robledo; Juan-José Granizo; Pilar Coronel
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

3.  Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar.

Authors:  J Picazo; J Ruiz-Contreras; J Casado-Flores; E Giangaspro; F Del Castillo; T Hernández-Sampelayo; E Otheo; F Balboa; E Ríos; C Méndez
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

4.  Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).

Authors:  Emilio Pérez-Trallero; Jose E Martín-Herrero; Ana Mazón; Celia García-Delafuente; Purificación Robles; Victor Iriarte; Rafael Dal-Ré; Juan García-de-Lomas
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

5.  Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model.

Authors:  Fabio Cafini; Jose Yuste; Maria-Jose Giménez; David Sevillano; Lorenzo Aguilar; Luis Alou; Elisa Ramos-Sevillano; Martha Torrico; Natalia González; Ernesto García; Pilar Coronel; Jose Prieto
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

6.  Update on the clinical utility and optimal use of cefditoren.

Authors:  José Barberán; Lorenzo Aguilar; María-José Giménez
Journal:  Int J Gen Med       Date:  2012-05-21

Review 7.  Cefditoren in upper and lower community-acquired respiratory tract infections.

Authors:  Francisco Soriano; María-José Giménez; Lorenzo Aguilar
Journal:  Drug Des Devel Ther       Date:  2011-02-09       Impact factor: 4.162

8.  Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008.

Authors:  Matthias Imöhl; Ralf René Reinert; Christina Mutscher; Mark van der Linden
Journal:  BMC Microbiol       Date:  2010-11-25       Impact factor: 3.605

9.  Drug resistance in community-acquired respiratory tract infections: role for an emerging antibacterial.

Authors:  Lorenzo Aguilar; María-José Giménez; José Barberán
Journal:  Infect Drug Resist       Date:  2010-06-18       Impact factor: 4.003

10.  Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model.

Authors:  Mustafa Bakır; Ozden Türel; Oleksandr Topachevskyi
Journal:  BMC Health Serv Res       Date:  2012-11-09       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.